Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Verisante Technology Inc. V.VRS


Primary Symbol: V.VER.H

Verisante Technology Inc is a Canada based medical device company. It is engaged in commercializing medical systems for the early detection of cancer. The products of the company are Verisante Aura which is for skin cancer detection and Verisante Core which is for lung, colon and cervical cancer detection. It utilizes a cancer detection platform while the operating software and probe technology. The group generates revenue from the sale and renting of its medical devices.


TSXV:VER.H - Post by User

Bullboard Posts
Comment by Kantenahon Jan 08, 2008 6:50pm
365 Views
Post# 14171203

RE: Patience is required.

RE: Patience is required.Hello Hoboman1 - welcome to the Allen-Vanguard bullboard.

Here is a brief summary of some of the relevant facts as I see them.  The first and most obvious place to look is the company's most recent financial results (FY 2007 ended Sept. 30/07) .  A few highlights:

- Q4 revenue was $50.0 million, with EBITDA of $8.4 million (net of a one time inventory charge of $1.2 million), up from revenue of $20.0 million and EBITDA of $2.9 million in Q4 of FY 06.

- Revenue and EBITDA for FY 07 was $96.2 million and $10.0 million, respectively, up from $56.8 million and $4.3 million, respectively, in FY 06.

- VRS entered fiscal 2008 with a backlog of $135 million (more than enough to beat FY 2007's revenue numbers) 

- The company continues to generate healthy cash flow (cash at end of FY 2007 was $20.4M vs. $5.7M at end of FY 2006).

-  Gross Margin remains strong - in the 40% range.

- acquisition of Med-Eng at the end on FY 2007 is a good fit for VRS and represents opportunity to leverage growth for FY 2008 and beyond.

- IED's remain the number one threat for NATO troops in Iraq and Afghanistan.  VRS is a leader in counter-IED measures.

If you are so inclined, you may also want to refer to analyst coverage such as Versant, although I am always leery of such sources as they often have a vested interest in the performance of the stock.
https://www.grandich.com/reports/versant.01.07.08.pdf" target=_blank>https://www.grandich.com/reports/versant.01.07.08.pdf

Having said all of this, I am still of the opinion that VRS will continue to suffer, in the short-term, given the negative sentiment that dominates the market.  Therefore, delaying your purchase by a couple of months may prove to be a very wise & lucrative decision.

In the spirit of open and well-rounded debate, I invite all participants on this bullboard (particularly saniyya and MestQalander) to provide us with facts to support a more negative long-term view of this stock.  I am always open to new information and fact-based opinion.

I hope this helps Hoboman1 - Happy Investing!
 
Bullboard Posts